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Abstract
Cystic Fibrosis (CF) is accompanied with heightened inflammation worsened by drug resistant
Burkholderia cenocepacia. Human CF macrophage responses to B. cenocepacia are poorly
characterized and variable in the literature. Therefore, we examined human macrophage responses
to the epidemic B. cenocepacia J2315 strain in order to identify novel anti-inflammatory targets.
Peripheral blood monocyte derived macrophages were obtained from 23 CF and 27 non-CF
donors. Macrophages were infected with B. cenocepacia J2315 and analyzed for cytokines,
cytotoxicity, and microscopy. CF macrophages demonstrated significant increases in IL-1β, IL-10,
MCP-1, and IFN-γ production in comparison to non-CF controls. CF patients on prednisone
exhibited globally diminished cytokines compared to controls and other CF patients. CF
macrophages also displayed increased bacterial burden and cell death. In conclusion, CF
macrophages demonstrate exaggerated IL-1β, IL-10, MCP-1, and IFN-γ production and cell death
during B. cenocepacia infection. Treatment with corticosteroids acutely suppressed cytokine
responses.
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Cystic Fibrosis (CF) is the most common life-limiting autosomal recessive disease among
people of European descent, affecting over 70,000 people worldwide [1]. CF causes a wide
range of systemic symptoms due to viscous mucus plugging in epithelial lined organs, but is
most recognized for chronic, progressive respiratory infections which contribute to over
85% of patient deaths [2]. One of the major contributors to the chronic respiratory symptoms
of CF patients is an exaggerated systemic and lung inflammatory state with sustained pro-
inflammatory mediators present in CF patients from an early age in response to infection [3],
as well as neutrophilic lower airway inflammation independent of infection [4]. An area of
investigation into the sustained pro-inflammation in CF has been the role of polymorphisms
in IL-1β genes that are thought to help modulate CF lung disease, as patients with similar
genotypes often manifest different disease phenotypes based on their particular
polymorphism [5]. CF patients identified with two particular IL-1β gene single nucleotide
polymorphisms demonstrated increased long term disease severity, underscoring the
importance of IL-1β in CF and implicating a contribution of genetic variation in IL-1β in the
overall pathogenesis of lung function decline in CF [5].
CF patients are affected by numerous bacterial pathogens, but a particularly pathogenic
bacterium among CF patients is Burkholderia cenocepacia. This microorganism is a member
of the Burkholderia Cepacia Complex, which is known to cause exaggerated inflammation
in CF patients and is rapidly transmissible from patient to patient [6,7,8]. Clinical disease
can range from a severe and often fatal sepsis state termed ‘cepacia syndrome’, to a chronic
progressive deterioration of CF lung disease associated with worsened outcomes for CF
patients [9]. Due to poor lung transplant post-operative outcomes and high antibiotic
resistance, infection with B. cenocepacia is usually an exclusion criterion from lung
transplant eligibility in most centers, thereby offering little hope to infected CF patients for
prolonged survival [10,11]. B. cenocepacia can also infect patients with chronic
granulomatous disease (CGD), a disorder characterized by defective microbial phagocytosis
and increased caspase-1 dependent IL-1β production in the absence of reactive oxygen
species [12].
Because of the refractory nature and sustained inflammation of B. cenocepacia infections in
CF, we are investigating inflammatory pathways to better understand responses to CF
pathogens and uncover new therapeutic targets. Recently, we demonstrated that murine CF
macrophages had increased IL-1β release in response to B. cenocepacia infection in
comparison to normal controls [13]. Murine models also demonstrated a caspase-1
dependent IL-1β production similar to that seen in CGD [13]. However, human CF studies
are varying in the reported impact of IL-1β production, and incomplete in characterization
of responses to B. cenocepacia infection. Longitudinal studies have shown very little change
in IL-1β production over the first years of life [14], whereas others have shown increased
IL-1β within subsets of CF patients infected with viruses or various bacterial pathogens [3].
In addition, non CF human macrophages have demonstrated increased IL-1β in response to
B. cenocepacia [15], but it is unclear how this response compares to CF macrophages and
the overall impact on inflammation in CF. In this study, using the virulent B. cenocepacia
J2315 strain, we found increased levels of IL-1β, IL-10, MCP-1, and IFN-γ in infected
human CF macrophages, along with increases in cell death and bacterial survival compared
to non CF macrophages
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Bacterial strains and culture
Burkholderia cenocepacia strain J2315 was originally isolated from a CF patient of the
prototypic epidemic ET12 lineage [16]. Strain J2315 was the index strain from which
patient-to-patient spread of this lineage was first reported in Edinburgh, Scotland [17]. The
bacterial strain was grown in Luria-Bertani (LB) broth at 37°C overnight with high
amplitude shaking.
Monocyte-derived Macrophages (MDMs) with Ethics Statement
Monocytes were isolated from heparinized blood of 23 CF and 27 non CF human donors
aged 2–46 years (mean CF 23.4 years, non CF 23 years). Patient demographics are listed in
Table 1. No patients were colonized with B. cenocepacia and subjects were excluded if on
any chronic immunosuppressants. Non CF patients represented a mixed population of
healthy volunteers and asthma exacerbations to represent a model of airway inflammation
for comparison to CF. 5 CF and 3 non CF patients received 60mg of prednisone one time
16–20 hours prior to blood collection as part of their clinical care. Written informed consent
was obtained from all subjects as approved by the Institutional Review Board of Nationwide
Children’s Hospital. Written consent from legal guardians of minors was obtained as well as
written assent from minors aged 9 to 17 years. Monocytes were separated from the whole
blood using Ficol-Hypaque (Sigma). Isolate monocytes were re-suspended in RPMI (Gibco)
plus 10% human AB serum (Lonza) to a concentration of 2 × 10^6 cells/mL and incubated
for 5 days at 37°C. On day 5 macrophages were isolated and infected with J2315 at a
multiplicity of infection (MOI) of 10.
Bioplex
MDMs were infected with J2315 for 24 hours and the culture supernatant was collected,
centrifuged, and stored at −20°C until assayed for cytokine content. The concentration of
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, IFN-γ, MCP-1, GM-
CSF, G-CSF, and MIP-1β in the supernatant was determined by Bioplex assay following the
manufacturer’s protocol (BioRad, Hercules, CA).
Enzyme-Linked Immuno Sorbent Assay (ELISA)
MDMs were infected with J2315 for 24 hours and culture supernatants were centrifuged and
stored at -20°C until assayed for cytokine content. The quantification of IL-1β, IL-8, IL-10,
and TNF-a in the supernatant was determined by sandwich ELISA following the
manufacturer’s protocol (R&D system Inc, Minneapolis, MN, USA) as previously described
[18].
Cytotoxicity
MDMs were infected with J2315 for 24 hours and the culture supernatants were collected
and centrifuged. Histone-associated DNA fragments were detected using the cytotoxicity
detection photometric assay kit according to the manufacturer’s protocol (Roche Applied
Science, Indianapolis, IN). Experiments were performed in triplicate.
Confocal Microscopy
2.0 × 105 MDMs cultured on 12 mm glass cover slips in 24 well tissue culture plates were
infected synchronously with J2315 at an MOI of 10. Nuclei were stained with the nucleic
acid dye 4′,6′-diamino-2-phenylindole (DAPI) and converted to green for pictures.
Lysosomes were stained red with Lysotracker Red (L7528, Invitrogen, Carlsbad, CA). One
hundred bacteria were scored for each condition, and scoring was verified by blinded
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reviewers. Experiments were performed in triplicate. Samples were analyzed with an
Olympus FV10i Spectral Confocal microscope.
Transmission Electron Microscopy
MMDs were isolated and infected with J2315 at an MOI of 10 for 2 hours. Cells cultured on
Permanox (Lab-Tek) chamber slides were fixed with 2.5% gluteraldehyde in 0.1M
phosphate buffer with 0.1M sucrose. These were post fixed with 1% osmium tetroxide in
phosphate buffer then en bloc stained with 2% uranyl acetate in 10% ethanol, dehydrated in
a graded series of ethanols and embedded in Eponate 12 epoxy resin (Ted Pella Inc. USA).
Ultrathin sections were cut on a Leica EM UC6 ultra microtome (Leica microsystems,
Germany), collected on copper grids, and then stained with lead citrate and uranyl acetate.
Images were acquired with an FEI Technai G2 Spirit transmission electron microscope (FEI,
USA), Macrofire (Optronics) digital camera and AMT image capture Software.
Statistical Analysis
Statistical Analysis was performed using GraphPad Prism software (version 5.0). Unpaired
t-tests and ANOVA were used when appropriate. Statistical significance was determined
with a two-tailed p < 0.05.
RESULTS
IL-1β, IL-10, MCP-1, and IFN-γ are increased in blood MDMs derived from CF patients
infected with J2315
Previous murine models have demonstrated increased pro-inflammatory IL-1β production in
CF macrophages after infection with B. cenocepacia K56–2, but studies in humans are
controversial [19,20]. Therefore, we assessed multiple inflammatory cytokines to determine
differential responses to the J2315 strain in CF patients. Human CF and non CF peripheral
MDMs were infected for 24 hours with the J2315 strain of B. cenocepacia and supernatants
of infected macrophages were collected and analyzed for IL-1β, IL-10, MCP-1, and IFN-γ
release. IL-1β, IL-10, MCP-1, and IFN-γ production was significantly increased in
macrophages derived from CF patients compared to non CF controls (Figure 1A–D). P
values were 0.0105 (IL-1β), 0.0478 (IL-10), <0.001 (MCP-1) and 0.025 (IFN-γ). There was
no significant difference in cytokine production between male and female patients (data not
shown). There was also no difference when comparing CF patients to matched non CF
asthmatic and healthy controls. These results demonstrate that both pro inflammatory IL-1β,
MCP-1, and IFN-γ and anti-inflammatory IL-10 are increased in production in response to
B. cenocepacia infection in macrophages from CF patients. There was no significant
difference in IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-12, IL-13, IL-17, GM-CSF, G-CSF,
MIP-1β, and TNF-α production between CF and non CF patients in response to J2315
infection (data not shown). These results indicate that although these cytokines may be
important in other CF pathogen states, their production is not increased in response to B.
cenocepacia infections in CF patients.
Corticosteroids decrease inflammatory and anti-inflammatory cytokine production from
CF monocyte-derived macrophages
Although control of heightened inflammation during B. cenocepacia infection is extremely
difficult, corticosteroids have been shown to be acutely beneficial in case reports of
Burkholderia cepacia sepsis [21]. We therefore analyzed cytokine production in five CF
patients (mean age 25.8 years) and three non CF patients (mean age 17 years) on
corticosteroid treatment. CF and non CF patients were given one dose of 60 mg prednisone
as part of their standard treatment 16–20 hours prior to blood isolation. Isolated MDMs were
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infected with J2315 for 24 hours and supernatants were analyzed. There was a significant
decrease in IL-1β, IL-10, MCP-1, and IFN-γ production in the CF patients on prednisone in
comparison to CF patients not on steroids (Figure 1A–D). Therefore, exaggerated pro and
anti-inflammatory responses in CF patients to B. cenocepacia infection may be substantially
reduced with corticosteroid treatment.
B. cenocepacia avoids lysosomal degradation in CF macrophages
Defective macrophage clearance of B. cenocepacia has been reported previously as a
potential contributor to B. cenocepacia virulence in CF [22,23,24]. We used confocal
microscopy to determine co-localization of J2315 to the lysosome where bacterial
degradation would take place to determine any differences in bacterial trafficking between
CF and non CF MDMs that could contribute to the increased inflammation seen in CF
MDMs. CF and non CF MDMs were infected with J2315 for 30 minutes and 1 hour and
then a fluorescent lysotracker label was added. Lysotracker label is weakly basic and
concentrates in the acidic lysosome. First, we scored the presence of bacteria associated per
100 macrophages. After 30 minutes of infection there was no significant difference in mean
bacteria present between CF and non CF macrophages (p value 0.4548), but at one hour post
infection there was a significant increase in bacteria present in CF macrophages compared to
non CF macrophages (Figure 2A–D, 3A–B, p value <0.0060). Second, we evaluated the
percent of bacteria localized with lysotracker red. After 30 minutes of infection there was a
significant increase in lysosomal co-localization of bacteria observed in non CF
macrophages (p value 0.010) with a continued significant increase in lysosomal co-
localization of bacteria after one hour in non CF macrophages (Figures 3C–D, p value
<0.0001). Taken together, these data indicate that B. cenocepacia avoids trafficking to the
lysosome in CF macrophages leading to increased bacterial survival.
B. cenocepacia bacterial burden is increased in CF macrophages
Given that B. cenocepacia avoids trafficking to the lysosome in CF MDMs, transmission
electron microscopy was used to further characterize the macrophage interaction with J2315
in CF and non CF patients. Macrophages were infected with J2315 for 2 hours and
transmission electron microscopy images were obtained as described in the methods. CF
macrophages infected with J2315 demonstrated an increased presence of active bacteria as
indicated by lipid droplets, with more than twice the amount of active bacteria present in the
CF macrophage compared to the non CF macrophage (Figure 4–AB). There was also an
increased number of bacteria with signs of degradation in the non CF macrophages (Figure
4B). Bacteria were noted to be in well defined vacuoles in the non CF macrophages (Figure
4B). These observations suggest that CF macrophages exhibit an increased bacterial burden
during B. cenocepacia infection.
Cell death is increased in macrophages derived from CF patients
To determine the correlation between increased inflammatory cytokine production and cell
injury, an LDH assay was performed to assess cell death. MDMs were infected for 24 hours
with J2315 and supernatants were assessed for LDH release. There was a significant
increase in cell death in CF macrophages compared to non CF macrophages after 24 hours
of infection with J2315 as measured by percent LDH release (not shown, p value 0.043). No
difference in basal cell death between the two groups in untreated macrophages was
observed. Therefore, increased cell death in CF patients is attributable to B. cenocepacia
infection and is not a baseline derangement in CF macrophages.
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Cystic Fibrosis patients endure exaggerated inflammation that is further increased during B.
cenocepacia infections leading to poor clinical outcomes and may result in rapid death [8,9].
While ongoing research into potential curative therapies for CF is promising, patients
currently infected with B. cenocepacia continue to suffer from poor outcomes and pose
serious risks for transmitting infection to other patients due to a lack of effective
therapeutics. It is therefore vital to develop new medications to help combat the heightened
inflammatory cascade observed in these infections.
While an increased IL-1β inflammatory response to B. Cenocepacia has been previously
demonstrated in murine models of CF [19,20], human CF macrophage responses to B.
cenocepacia are still poorly characterized with controversial findings. Previous studies have
shown normal IL-1β levels in young CF patients not infected with B. cenocepacia [14,25],
elevated levels in adult CF alveolar macrophages not infected with B. cenocepacia [26], and
increased IL-1β in non CF macrophages in response to B. cenocepacia [15]. Therefore, it is
not clear if IL-1B is specifically increased in CF macrophages upon B. cenocepacia
infection. Here we demonstrate exaggerated human macrophage IL-1β responses to B.
cenocepacia J2315. Given the findings in this study, in addition to the availability of anti-
IL-1β monoclonal antibodies which have proven efficacy in clinical syndromes
characterized by excessive IL-1β production [27], IL-1β could prove to be an interesting
target for acute and chronic B. cenocepacia infections in CF patients.
Additionally, we also demonstrate evidence of increased MCP-1, IFN-γ and IL-10
production in CF patients. These findings may be related to the need for more effective
macrophage bacterial clearance and antigen presentation during infection as evidenced by
the increased bacterial burden in CF patients seen using microscopic analysis. Interestingly,
IFN-γ has been shown to be an effective therapy in CGD, the other clinical entity affected
by B. cenocepacia. In CGD, IFN-γ works by improving the phagocytic clearance of
apoptotic cells [28] and therefore could be another target of similar clinical application in
CF patients. Previous studies have also shown a protective role for MCP-1 in Burkholderia
mallei infections and a close relationship with IFN- in order to clear pulmonary infection
[29]. IL-10’s role in CF is less clear, but decreases in IL-10 production are thought to
contribute to airway inflammation present during acute and chronic infections [30].
However, the acute increase in IL-10 seen in this study must be taken with caution, as
elevated IL-10 has been linked to immunoparalysis and poor outcomes during sepsis states
[31], which would need to be considered in the treatment of ‘cepacia syndrome’. All
together these findings lend further support to our theory that the aberrations in the
cytokines observed in this study may be appropriate targets for future therapeutic
interventions.
In addition to potential specific cytokine directed therapies, there have been reports of cases
of B. cepacia sepsis alleviated by corticosteroids [21], but the exact influence of broad
immunomodulators such as corticosteroids acutely and chronically remains to be elucidated
in CF patients with B. cenocepacia infection. The markedly diminished inflammatory
responses observed in the subset of CF patients who had been placed on corticosteroids prior
to infection, suggests the possibility of acutely blocking the intense inflammatory response
elicited by B. cenocepacia through broad immunosuppression. However, the exact timing
and duration of steroid therapy needs to be clarified in future studies examining human
macrophage responses as the patients in this study received corticosteroids prior to infecting
their macrophages.
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In summary, CF macrophages have exaggerated inflammatory responses to B. cenocepacia
infection along with host trafficking defects that are potential targets of future studies and
therapeutic interventions.
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CF macrophages produce excess IL-1β, IL-10, MCP-1, and IFN-γ during B.
cenocepacia infection
B. cenocepacia avoids lysosomal degradation in CF macrophages
Corticosteroids may blunt exaggerated inflammatory responses to B. cenocepacia
infection
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Figure 1. Cytokine concentrations
(A) IL-1β, (B) IL-10, (C) MCP-1, and (D) IFN-γ levels for CF and non CF human MDMs
infected with B. cenocepacia J2315 for 24 hours. CF patients on steroids were on 60 mg of
prednisone daily at collection. Supernatant concentrations are in pg/mL.
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Macrophage derived blood monocytes from CF (A, C) and non CF patients (B, D) were
infected with J2315 for 30 minutes (A, B) and 1 hour (C,D) and examined by confocal
microscopy. The white arrow highlights increased bacteria. The nucleus is bright green,
lysosome stained red, and bacteria displayed in dark green. Co-localization of bacteria in the
lysosome is indicated in yellow and increased co-localization in non CF macrophages is
marked by a yellow arrow.
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Figure 3. Confocal microscopy scoring
CF and non CF macrophages infected with B. cenocepacia J2315. Mean bacteria presence
per 100 macrophages after 30 minutes (A) and 1 hour (B). Percent co-localization of
bacteria to the lysosome after 30 minute infection (C) and 1 hour (D).
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Figure 4. Electron microscopy data
Macrophages derived from blood monocytes of CF (A) and non CF (B) patients were
infected with B. cenocepacia for 2 hrs, and then processed for electron microscopy. The
black arrow indicates degraded bacteria and the white arrow indicates active bacteria.
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Table 1
Patient Demographics
Cystic Fibrosis Non Cystic Fibrosis
Age (mean years) 23.4 23.0
Caucasion 100% 100%
Male 50% 48%
P. aeruginosa colonization 62% N/A
MRSA colonization 33% N/A
Average FEV1 % predicted 50% +/− 23% N/A
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